Monday, April 28, 2025

These Male Octopuses Paralyze Mates During Sex to Avoid Being Eaten Alive

Male blue-lined octopuses paralyze their mates to survive the perils of reproduction.


by Tudor Tarita
April 25, 2025
ZME Science
Edited and reviewed by Mihai Andrei



A male blue-lined octopus mounts a female during mating and injects venom into her body. Credit: Wen-Sung Chung/University of Queensland


It’s not uncommon for sex in nature to include a bit of violence. But in the shadowy tide pools and coral reefs of the Pacific, an extraordinary mating duel is unfolding. The blue-lined octopus (Hapalochlaena fasciata), a tiny but deadly cephalopod, has developed a unique and ruthless solution to a longstanding problem: surviving mating.

A Deadly Embrace


Sexual cannibalism is common in cephalopods. Female octopuses are larger, stronger, and when opportunity strikes, perfectly willing to turn their mates into a meal. “When female blue-lined octopuses lay eggs, they spend roughly six weeks without feeding just looking after the eggs. They really need a lot of energy to get them through that brooding process,” Dr. Wen-Sung Chung of the University of Queensland told The Guardian. For males, this poses a life-or-death dilemma: how do you pass your genes without becoming past tense?



Image in creative commons.


As smart as they are, the blue-lined octopus males came up with a radical solution. New research reveals that males inject their mates with venom mid-copulation, paralyzing them just long enough to ensure mating success. The venom, a neurotoxin called tetrodotoxin, is one of the most potent in nature—powerful enough to kill humans and even green sea turtles that accidentally ingest the octopus. Yet, in a similar fashion, female blue-lined octopuses have evolved resistance to their own species’ lethal weapon. While it renders them temporarily immobile, they suffer no lasting effects.


Envenomation by blue-lined octopuses can be deadly to humans. Credit: Wen-Sung Chung/University of Queensland

A High-Stakes Strategy


Chung and his colleagues at the University of Queensland observed male blue-lined octopuses delivering a targeted bite near the female’s aorta at the start of ‘sexy time’. As the venom took effect, the females turned pale, their breathing slowed, and their pupils became unresponsive to light. The paralysis lasted roughly eight minutes. Mating itself, however, extended far longer—lasting between 40 and 75 minutes.


Males of some octopus species have found other ways to avoid being eaten. The argonaut octopus, for instance, takes no chances—its males simply detach their mating arm, which drifts toward the female to deposit sperm, sparing the male from a potentially fatal encounter. Others, like deep-sea octopuses, have evolved elongated mating arms to fertilize females from a safe distance.

But blue-lined octopuses, with their much shorter mating arm, must get up close and personal.

The venom-assisted strategy ensures the male can finish the job and escape before the female regains control. “This is a great example of a co-evolutionary arms race between sexes, where a cannibalizing large female is counteracted using venom in males,” Chin-Chuan Chiao of National Tsing Hua University in Taiwan, who was not involved in the study, told New Scientist.

Males seem to be equipped for this battle of the sexes. The study found that male blue-lined octopuses have significantly larger venom glands than females. It’s an evolutionary arms race in miniature—females grow bigger, stronger, and more dangerous, and in response, males evolve an efficient chemical countermeasure to stay alive long enough to reproduce.

Life After the Encounter? Not that long

Despite their clever mating strategy, neither sex has long to live. Like most octopus species, the blue-lined octopus follows a reproductive pattern known as semelparity—mating once before dying. Males perish shortly after copulation. Females, once their eggs hatch, succumb soon after. Their venom ensures that their genes live on, even if they do not.

As researchers continue to study the blue-lined octopus’s reproductive behavior, one thing is clear: in the game of evolution, sometimes the only way to survive is to fight fire… uhm… venom with venom.

 

Effect of coupled wing motion on the aerodynamic performance during different flight stages of pigeon




Beijing Institute of Technology Press Co., Ltd
Overview of the pigeon flight experiment and wing model 

image: 

 (A) The flight experiment scene consists of a 16 m × 5 m × 3 m space, with 30 motion capture cameras set up. The pigeon takes off from a perch at one end and lands at the other. (B) Markers on the pigeon’s body and wings include 12-mm spherical markers, 8-mm spherical markers, and 5-mm × 2.5-mm paper markers. (C) 3D wing model, representing the right wing of the pigeon

view more 

Credit: Yishi Shen, Beijing Institute of Technology.





A research paper by scientists at Beijing Institute of Technology presented a CFD simulation method based on biological experimental data to analyze the aerodynamic performance of pigeons during takeoff, leveling flight, and landing in free flight.

The research paper, published on Mar. 11, 2025 in the journal Cyborg and Bionic Systems.

Birds achieve remarkable maneuverability in takeoff, steady flight, and landing by continuously and adaptively morphing their wing shape, yet existing bio-inspired flapping-wing aerial vehicles still struggle to replicate these capabilities. Prior research has often simplified avian wing kinematics to isolated flapping, twisting, or folding motions or relied on static scanning and wind-tunnel models, failing to capture the true coupled deformations of freely flying birds. “Moreover, three-dimensional reconstructions of medium-sized birds like pigeons have been limited by experimental space, occlusion of key joint positions, and constrained degrees of freedom, leaving the full cycle of natural wing morphing poorly understood.” said the author Yishi Shen, a researcher at Beijing Institute of Technology, “Consequently, there is an urgent need for experimental measurements of real pigeon wing motion in free flight to build a true three-dimensional coupled wing model and employ computational fluid dynamics to uncover the aerodynamic mechanisms underlying different flight stages.”

In this paper, authors propose a CFD simulation method based on biological experimental data to analyze the aerodynamic performance of pigeons during takeoff, leveling flight, and landing in free flight. Firstly, authors used 30 motion capture cameras in a 16 m × 5 m × 3 m space to collect the wing movement data of pigeons throughout the entire free flight process. Secondly, authors decoupled and analyzed the complex coupled wing movements into 5 kinematic parameters: flapping, twisting, sweeping, folding, and bending. A wing model was constructed to conduct aerodynamic simulations by simplifying the scanned wing surface profiles. The wing’s movements were defined using rotation matrices employed in the simulation process. To better understand the aerodynamic mechanisms of the wings during 3 different stages, authors used CFD methods to analyze the aerodynamic characteristics of the coupled movements of the 5 kinematic parameters. Furthermore, authors provided a detailed analysis of the flow field structures during each process.

This study found that, within a wingbeat cycle, pigeons during the takeoff stage cause the leading-edge vortex to attach earlier, enhancing instantaneous lift to overcome gravity and achieve ascending. During the leveling flight stage, the pigeon’s average lift becomes stable, ensuring a steady flight posture. In the landing stage, the pigeon increases the wing area facing the airflow to maintain a stable landing posture, achieving a more minor, consistent average lift while increasing drag. “Our study enhances our understanding of birds’ flight mechanisms and provides theoretical guidance for developing efficient bio-inspired flapping-wing aerial vehicles.” said Yishi Shen.

Authors of the paper include Yishi Shen, Yi Xu, Weimin Huang, Chengrui Shang, and Qing Shi.

This work was supported in part by the National Natural Science Foundation of China under grants 61933001, U2013208, and 62088101.

The paper, “Effect of Coupled Wing Motion on the Aerodynamic Performance during Different Flight Stages of Pigeon” was published in the journal Cyborg and Bionic Systems on Mar. 11, 2025, at DOI: 10.34133/cbsystems.0200.

 

Donor lungs safely preserved up to 20 hours out-of-body prior to transplantation



International Society for Heart and Lung Transplantation





27 April 2025, Boston—A study on donor lungs preserved outside the body before transplantation demonstrated that the hypothermic oxygenated machine perfusion (HOPE) technique is a safe and effective lung preservation method, even with total out-of-body times approaching 20 hours.

 

Jitte Jennekens, MSc, organ perfusionist/transplant coordinator at the UMC Utrecht in the Netherlands, presented the study results at today’s Annual Meeting and Scientific Sessions of the International Society of Heart and Lung Transplantation (ISHLT) in Boston.

 

“This technique is being used to preserve donor livers and kidneys and is being studied in clinical trials for hearts, but it hasn't gotten that much attention for lung preservation yet,” said Jennekens.

 

Ex vivo lung perfusion (EVLP) is a technique that allows for donor lungs to be maintained, assessed, and potentially reconditioned outside of the body before transplantation. The lungs are connected to a pump and a ventilator and perfused with a solution that functions as a physiological fluid.

 

The UMC Utrecht developed its HOPE protocol to safely extend perfusion times, to maintain the viability of the lungs overnight until the transplantation can be performed during the day.

 

Donor lungs selected for EVLP are typically transported on ice and then warmed to 37 degrees Celsius using a normothermic EVLP (called nEVLP) protocol for functional assessment. Following nEVLP, the lungs are then returned to ice until the transplant begins.

 

The HOPE protocol eliminates the second period on ice by assessing the lungs during one hour of nEVLP and then preserving the lungs at 12 degrees C until the procedure.

 

Jennekens presented data comparing the outcomes of 12 cases conducted using the nEVLP-HOPE protocol with a historical cohort of donor lungs transplanted directly into patients without ex vivo lung perfusion. 

 

The control cohort included 118 cases of lungs transplanted directly without perfusion between 2017 and 2022. The cases were performed between 2022 and 2024 using the HOPE protocol for logistical reasons.

 

No lungs in the nEVLP-HOPE group were rejected for transplantation, and short-term outcomes were similar between the study and control groups.

 

“Our findings indicate that HOPE is a safe and effective lung preservation method after a period of normothermic EVLP,” Jennekens said.

 

Jennekens said the next step is to determine the preservation strategy that will be most beneficial to a specific type of donor lung.

 

“Extending perfusion times for donor lungs outside of the body will allow for a future in which donor lungs can be optimized with different therapies,” she said.

 

END

 

DCD heart transplantation reaches 10-year mark, now up to 30% of transplant volumes


Transplantation method offers comparable outcomes


International Society for Heart and Lung Transplantation





27 April 2025, Boston—Researchers at the Annual Meeting and Scientific Sessions of the International Society of Heart and Lung Transplantation (ISHLT) marked the 10-year anniversary of modern heart donation after circulatory death (DCD), a technique that has significantly increased transplant volumes around the world.

Sarah Scheuer, MD, PhD, said that most centers that have started a DCD program experience an approximately 30 percent increase in their transplant volume.

“It’s arguably the biggest shift in heart transplantation since the introduction of modern immunosuppression,” she said.

In a DCD transplant, the heart comes from a donor whose circulatory and respiratory functions have stopped but who did not meet criteria for brain death.

“The first heart transplants performed in the ‘60s and ‘70s all preceded the legislation surrounding brain death, so in essence, they were DCD,” said Dr. Scheuer, MD, PhD, a cardiothoracic surgeon trainee at St. Vincent’s Hospital in Sydney, Australia.

After brain death criteria were established in 1981, donation after brain death (DBD) was the predominant source of donated hearts for nearly five decades.

The first modern DCD heart transplant was performed at St. Vincent’s Hospital in 2014; the Royal Papworth Hospital in Cambridge, England, followed with their first in 2015. The modern DCD pathway was developed over a 10-year period of research and laboratory work conducted in Australia and the UK, both of which are challenged by the limited availability of donor organs.

In 2022, a randomized, controlled trial in the United States showed that transplantation outcomes with DCD hearts were comparable to traditional (DBD) hearts.

“The successful US trial led to a real explosion of the field within the USA with increasing numbers of centers starting modern DCD heart transplant programs,” Dr. Scheuer said. “It’s a huge impact on the availability of donor hearts.”

Over the past decade, 123 DCD hearts have been transplanted as part of the St. Vincent’s DCD program, and 134 DCD hearts have been transplanted at Royal Papworth Hospital.

“Papworth and St. Vincent's have both had a long history of innovation and research within our heart transplant programs,” said Dr. Scheuer. “We’re always pushing the boundaries, partially out of necessity, and also out of a desire to offer transplantation to more people because, in many ways, it’s the best treatment for end-stage heart failure.”

Dr. Stephen Pettit, a transplant lead and consultant cardiologist at Royal Papworth Hospital, said DCD heart transplantation is gradually spreading worldwide, increasing the use of hearts that otherwise could not have been donated.

“Families of potential organ donors, who must give permission before organs are donated in the UK, have been very supportive of DCD heart transplantation,” Dr. Pettit said. “The DCD process makes sense to families who sometimes struggle with the concept of brain death.”

Researchers are looking for biomarkers to help identify whether DCD hearts are in good condition before transplantation and exploring less costly options for preserving the donor heart (called perfusion) during transportation. A shift toward regenerative medicine is also on the horizon.

“We may get to the point where we put a heart on a perfusion or preservation device and spend the next few hours effectively improving the function of that organ,” said Dr. Scheuer. “I think we'll also get more clarity on the best method of preserving hearts during DCD transplantation.”

For now, she’s gratified by the many lives changed by transplantation, including a St. Vincent patient who received a DBD heart as a teenager and, more recently, a second DCD heart in his 40s.

“We're at a point with heart transplantation where some patients will live a relatively normal duration of life,” she said. “I don't think we have any other treatment for heart failure that can offer that potential outcome.”

 

END



Donor hearts are traveling longer distances with machine perfusion



International Society for Heart and Lung Transplantation


 

 


Technology Could Pave the Way to International Heart Exchange

 27 April 2025, Boston—In places like Australia, where metropolitan areas are separated by an entire continent, donor hearts used to go unused simply because transplant teams couldn’t get the organ to a recipient in time.

“If there isn’t a recipient for an available heart in Perth but there’s a match in Sydney, that's nearly 2,000 miles of travel, or a five-hour flight,” said Emily Granger, MBBS, cardiothoracic and heart and lung transplant surgeon at St. Vincent's Hospital, Sydney, Australia. “Add to that a couple of hours for retrieval and preparation, and that’s a seven-hour journey.”

Dr. Granger addressed organ transportation time at today’s Annual Meeting and Scientific Sessions of the International Society of Heart and Lung Transplantation (ISHLT) in Boston.

“We’ve focused much of our research at St. Vincent's on ensuring that we can protect and preserve the donor heart not only for a long distance but also for a long time,” she said. 

Until recently, donor hearts had to be transported in a portable cooler, which gave transplant teams six hours to get a donor heart implanted. The inception of machine perfusion, in which a device pumps a blood-like solution through the donor heart during transport, has significantly extended that window. 

St. Vincent’s, a pioneer of machine perfusion, began using the technology in 2014 for hearts donated following circulatory death (DCD). Today, machine perfusion is used in over half of the center’s heart transplants.

“We recognized that we needed a system that would enable us to span the country,” she said. “We knew we had to remove time from the equation.”

St. Vincent has pushed the limits of normothermic machine perfusion (NMP), in which the heart is perfused and preserved at approximately 35 degrees Celsius, for up to 8 hours. Other Australian units have even used the system for 10 hours.

“Ten years ago, we had to refuse donor organs because of time constraints,” she said. “Now we can accept organs from regions we never thought were possible and be confident they’ll work.”

She said in the near future, it may be possible to push the boundaries even more. 

“We could actually look at an international exchange of donor hearts to allow transport between countries,” she said. 

Australia already retrieves donor organs from New Zealand; however, machine perfusion could allow transplantation teams to travel to the Pacific Islands and Asia.

“There are a significant number of patients on our transplant list that are very difficult to match to a donor,” she said. “The answer for them could be a donor from a slightly different genetic population than we have in our local area. Their ideal donor might actually live in a different country.”

Research conducted at St. Vincent’s has shown that outcomes for heart transplants involving machine perfusion are comparable to transplants performed without it.

“We looked specifically at the primary graft function in the transplanted heart and found no difference across modalities,” she said. “We like to think that we're removing the impact of time by using machine perfusion.”

Dr. Granger said the technology represents a true sea change for heart transplant teams.

“When I began my career as a transplant surgeon, we just had a portable cooler,” she said. “The space has totally transformed, and the only thing limiting us at the moment is our imagination.”

END 



About ISHLT
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support, and innovative therapies via research, education, and advocacy. ISHLT members focus on transplantation and a range of interventions and therapies related to advanced heart and lung disease.

The ISHLT Annual Meeting and Scientific Sessions will be held from 27-30 April at the John B. Hynes Veterans Memorial Convention Center in Boston.

 

Dangerous synthetic opioids and animal sedatives found in wastewater



University of South Australia




University of South Australia scientists have developed a highly sensitive method to detect illegal opioids and a veterinary sedative in Australia’s wastewater system, providing a vital early warning tool to public health authorities.

new study published in Environmental Science and Pollution Research, funded by the Australian Criminal Intelligence Commission and Preventative Health SA, explains the innovative wastewater-based testing method capable of identifying trace levels of nitazenes – a class of highly potent synthetic opioids – and xylazine, an animal sedative not approved for human use.

Nitazenes are among the most dangerous opioids ever synthesised, up to 1000 times more potent than morphine. Initially developed in the 1950s but never approved for clinical use, these substances have recently emerged in the illicit drug supply worldwide. Their extreme potency poses a significant risk of overdose, often with fatal consequences.

Xylazine, commonly used in veterinary medicine, is often added to illicit opioids such as fentanyl and heroin. It complicates overdose treatment because its effects cannot be reversed with naloxone, the standard emergency antidote for opioid toxicity. Moreover, xylazine use is associated with severe health impacts including sedation, respiratory depression, hypotension, and dangerous skin ulcerations.

“This is the first time a comprehensive suite of nitazene compounds and xylazine has been monitored in Australian wastewater,” says lead researcher UniSA Associate Professor Cobus Gerber.

“Our method can detect even minute levels, allowing us to track emerging threats before they escalate,” he says.

Over a three-day period in August 2024, researchers analysed 180 wastewater samples from 60 sites around Australia. They identified five different nitazenes in 3–6% of all samples. Alarmingly, xylazine was detected in 26% of all samples.

“Given the potency of nitazenes and the health complications associated with xylazine, even low-level detections are a red flag,” says co-first author Dr Emma Keller.

The research team developed a laboratory method using solid phase extraction and liquid chromatography–mass spectrometry (LC-MS/MS) to concentrate and identify target compounds. The method achieved up to 1000-fold enrichment, with limits of detection well below 1 ng/L for most substances.

Crucially, the method is adaptable and can be quickly updated to detect new derivatives as they emerge – an essential capability as drug manufacturers continue to tweak chemical structures to evade legislation.

“This analytical platform enhances Australia’s capacity to monitor and respond to the shifting landscape of illicit drug use,” says Assoc Prof Gerber. “It complements forensic analysis and can provide near real-time data to inform public health strategies.”

The results underscore the growing presence of harmful and often unsuspected substances in street-level drugs. In the United States, xylazine has already been detected in over 80% of fentanyl-containing paraphernalia and is implicated in an increasing number of overdose deaths.

“With similar patterns now being detected in Australia and nitazenes also infiltrating the stimulant market, there’s an urgent need to raise awareness and strengthen harm reduction responses,” Assoc Prof Gerber says.

“Comprehensive method to detect nitazene analogues and xylazine in wastewater” is authored by Emma L. Keller, Brock Peake, Bradley S. Simpson, Jason M. White and Cobus Gerber.
DOI: 10.1007/s11356-025-36425-0

 

 

Buprenorphine treatment in pregnancy and maternal-infant outcomes



JAMA Health Forum


About The Study: In this cohort study of pregnant individuals with opioid use disorder, buprenorphine treatment was associated with improved outcomes for the mother and infant, underscoring the need to improve access to treatment nationwide.



Corresponding Author: To contact the corresponding author, Stephen W. Patrick, MD, MPH, MS, email stephen.patrick@emory.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamahealthforum.2025.1814)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being presented at the Pediatric Academic Societies 2025 meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.1814?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=042725

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

 

 

Heart disease deaths worldwide linked to chemical widely used in plastics




NYU Langone Health / NYU Grossman School of Medicine



Daily exposure to certain chemicals used to make plastic household items could be linked to more than 356,000 global deaths from heart disease in 2018 alone, a new analysis of population surveys shows.

While the chemicals, called phthalates, are in widespread use globally, the Middle East, South Asia, East Asia, and the Pacific bore a much larger share of the death toll than others — about three-fourths of the total.

For decades, experts have connected health problems to exposure to certain phthalates found in cosmetics, detergents, solvents, plastic pipes, bug repellants, and other products. When these chemicals break down into microscopic particles and are ingested, studies have linked them to an increased risk of conditions ranging from obesity and diabetes to fertility issues and cancer.

Led by researchers at NYU Langone Health, the current study focused on a kind of phthalate called di-2-ethylhexyl phthalate (DEHP), which is used to make food containers, medical equipment, and other plastic softer and more flexible. Exposure has been shown in other studies to prompt an overactive immune response (inflammation) in the heart’s arteries, which, over time, is associated with increased risk of heart attack or stroke. In their new analysis, the authors estimated that DEHP exposure contributed to 356,238 deaths, or more than 13% of all global mortality from heart disease in 2018 among men and women ages 55 through 64.

“By highlighting the connection between phthalates and a leading cause of death across the world, our findings add to the vast body of evidence that these chemicals present a tremendous danger to human health,” said study lead author Sara Hyman, BS, an associate research scientist at NYU Grossman School of Medicine.

According to the authors, the resulting economic burden from the deaths identified in their study was estimated to be around $510 billion and may have reached as high as $3.74 trillion.

In a past study from 2021, the research team tied phthalates to more than 50,000 premature deaths each year, mostly from heart disease, among older Americans. Their latest investigation is believed to be the first global estimate to date of cardiovascular mortality — or indeed any health outcome — resulting from exposure to the chemicals, says Hyman, who is also a graduate student at NYU School of Public Global Health.

A report on the findings is publishing online April 29 in the journal Lancet eBiomedicine.

For the research, the team used health and environmental data from dozens of population surveys to estimate DEHP exposure across 200 countries and territories. The information included urine samples containing chemical breakdown products left by the plastic additive. Mortality data was obtained from the Institute for Health Metrics and Evaluation, a research group in the US that collects medical information worldwide to identify trends in public health.

Among the key findings, the study showed that losses in the combined region of East Asia and the Middle East and the combined region of East Asia and the Pacific accounted, respectively, for about 42% and 32% of the mortality from heart disease linked to DEHP. Specifically, India had the highest death count at 103,587 deaths, followed by China and Indonesia. The larger heart death risks in these populations held true even after the researchers adjusted their statistical analysis to take into account population size within the studied age group.

A possible explanation, the authors say, is that these countries face higher rates of exposure to the chemicals, possibly because they are undergoing a boom in plastic production but with fewer manufacturing restrictions than other regions.

“There is a clear disparity in which parts of the world bear the brunt of heightened heart risks from phthalates,” said study senior author Leonardo Trasande, MD, MPP. “Our results underscore the urgent need for global regulations to reduce exposure to these toxins, especially in areas most affected by rapid industrialization and plastic consumption,” added Trasande, the Jim G. Hendrick, MD, Professor of Pediatrics at NYU Grossman School of Medicine.

Trasande, who is also a professor in the Department of Population Health, cautions that the analysis was not designed to establish that DEHP directly or alone caused heart disease and that higher death risks did not take into account other types of phthalates. Nor did it include mortality among those in other age groups. As a result, the overall death toll from heart disease connected to these chemicals is likely much higher, he says.

Trasande says that the researchers next plan to track how reductions in phthalate exposure may, over time, affect global mortality rates, as well as to expand the study to other health concerns posed by the chemicals, such as preterm birth. Trasande also serves as director of NYU Grossman School of Medicine’s Division of Environmental Pediatrics and the Center for the Investigation of Environmental Hazards.

Funding for the study was provided by National Institutes of Health grant P2CES033423. Further study funding was provided by Beyond Petrochemicals.

Trasande has received support for travel or meetings from the Endocrine Society, World Health Organization, the United Nations Environment Programme, Japan’s Environment and Health Ministries, and the American Academy of Pediatrics. He has also received royalties and licenses from Houghton Mifflin Harcourt, Audible, Paidós, and Kobunsha, and has served in leadership or fiduciary roles at Beautycounter, Ahimsa, Grassroots Environmental Education, and Footprint. None of these activities were related to the current study. The terms and conditions of all of these relationships are being managed by NYU Langone Health.

In addition to Hyman and Trasande, other NYU Langone researchers involved in the study are Jonathan Acevedo, MPH, and Chiara Gianarelli, MD, PhD.

###

About NYU Langone Health
NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked NYU Langone No. 1 out of 115 comprehensive academic medical centers across the nation for three years in a row, and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise.

Media Inquiries:
Shira Polan
Phone: 212-404-4279
shira.polan@nyulangone.org

Link to interactive global map of excess cardiovascular mortality due to DEHP